Merck & Co., Inc. Business Combination, Contingent Consideration, Liability, Current
Merck & Co., Inc. (MRK) had Business Combination, Contingent Consideration, Liability, Current of $25.00 million as of 2025-03-31, per its 10-Q filed 2025-05-02.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2025-05-02
- 2025-03-31: Business Combination, Contingent Consideration, Liability, Current $25.00M.
- 2024-12-31: Business Combination, Contingent Consideration, Liability, Current $148.00M.
- 2024-09-30: Business Combination, Contingent Consideration, Liability, Current $163.00M.
- 2023-12-31: Business Combination, Contingent Consideration, Liability, Current $128.00M.
| Period end | Business Combination, Contingent Consideration, Liability, Current |
|---|---|
| 2025-03-31 | $25.00M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $148.00M 10-K · filed 2025-02-25 |
| 2024-09-30 | $163.00M 10-Q · filed 2024-11-06 |
| 2023-12-31 | $128.00M 10-K · filed 2024-02-26 |
| 2023-09-30 | $126.00M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $130.00M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $127.00M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $122.00M 10-K · filed 2023-02-24 |
| 2022-09-30 | $139.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $131.00M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $149.00M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $151.00M 10-K · filed 2022-02-25 |
| 2021-09-30 | $289.00M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $297.00M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $285.00M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $148.00M 10-K · filed 2021-02-25 |
| 2020-09-30 | $140.00M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $138.00M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $119.00M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $114.00M 10-K · filed 2020-02-26 |
| 2019-09-30 | $112.00M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $114.00M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $100.00M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $89.00M 10-K · filed 2019-02-27 |
| 2018-09-30 | $95.00M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $92.00M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $337.00M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $315.00M 10-K · filed 2018-02-27 |
| 2017-09-30 | $234.00M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $308.00M 10-Q · filed 2017-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |